RT Journal Article
SR Electronic
T1 Nigral volume loss in prodromal, early, and moderate Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.19.23294281
DO 10.1101/2023.08.19.23294281
A1 Langley, Jason
A1 Hwang, Kristy S.
A1 Huddleston, Daniel E.
A1 Hu, Xiaoping P.
A1 ,
YR 2023
UL http://medrxiv.org/content/early/2023/08/20/2023.08.19.23294281.abstract
AB The loss of melanized neurons in the substantia nigra pars compacta (SNc) is a hallmark pathology in Parkinson’s disease (PD). Melanized neurons in SNc can be visualized in vivo using magnetization transfer (MT) effects. Nigral volume was extracted in data acquired with a MT-prepared gradient echo sequence in 33 controls, 83 non-manifest carriers (42 LRRK2 and 41 GBA nonmanifest carriers), 65 prodromal hyposmic participants, 105 de novo PD patients and 26 48-month PD patients from the Parkinson’s Progressive Markers Initiative. No difference in nigral volume was seen between controls and LRRK2 and GBA non-manifest carriers (F=0.076; P=0.927). A significant main effect in group was observed between controls, prodromal hyposmic participants, and overt PD patients (F=5.192; P=0.002). Longer disease duration significantly correlated with lower nigral volume (r=-0.252; P=0.010). This study shows that nigral depigmentation can be robustly detected in prodromal hyposmic participants and overt PD patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the NIH-NINDS 1K23NS105944-01A1 (Huddleston), NIH-NIA 1U19AG071754-01 (Huddleston, Hu, Langley), the Department of Veteran Affairs 1I01RX002967-01A2 (Huddleston), the Emory American Parkinson's Disease Association Center for Advanced Research (Huddleston), the Emory Lewy Body Dementia Association Research Center of Excellence (Huddleston), and the Michael J Fox Foundation (MJF-10854, MJFF-010556; Huddleston, Hu, Langley).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data were provided by the Parkinson's Progressive Markers Initiative (PPMI) and can be downloaded at the following link: https://www.ppmi-info.org/access-data-specimens/dataI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the PPMI database (https://www.ppmi-info.org/access-data-specimens/data).